Kazunobu Ouchi MD, PhD.

1980-1982  Intern, Department of Pediatrics, National Okayama Hospital

1982-1983  Resident, Department of Pediatrics, National Okayama Hospital

1983-1986  Staff Doctor, Department of Pediatrics, National Okayama Hospital

1986-1987  Research Fellow, Division of Pediatric Infectious Diseases, University

of Oklahoma Health Science Center, Oklahoma City, OK, USA

1988-1989  Staff Doctor, Department of Pediatrics, National Kure Hospital

1989-2001  Vice Director, Department of Pediatrics, Saiseikai Shimonoseki General Hospital

2002~2006  Professor, Department of Pediatrics, Kawasaki Medical School

2006-2021  Chairman, Professor, Department of Pediatrics, Kawasaki Medical School

2016-      President, Japanese Society for Pediatric Infectious Diseases

2021-      Specially Appointed Professor, Department of Medical Welfare for Children, Faculty of Health and Welfare, Kawasaki University of Medical Welfare

Abstract:

In a recent couple of decade, macrolide-resistant Mycoplasma pneumoniae have increased in in children and special consideration in careful epidemiological observation and treatment has been required. We experienced several large epidemics of Mycoplasma pneumoniae pneumonia after the emergence of macrolide-resistant strains especially in east Asia. In addition, with the worldwide epidemic of COVID-19, the epidemic of mycoplasma pneumoniae infection has disappeared due to world-wide infection control measures in the society, however there may be some concern that a major epidemics of infections in children including Mycoplasma pneumoniae will occur after the COVID-19 epidemics subsides in the future. I think that we need to standardize treatment for Mycoplasma pneumoniae infection and I will mainly focus on our successful experience in Japanese guideline for the management of respiratory tract infection for children.